Lilly Buys Psychedelics Maker Atai Beckley for $2.8B
Eli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
Individual-focused guidance to tailor zero based budgeting to personal goals, with simple steps to stay committed and evolving.
19,433 articlesEli Lilly unveils a landmark $2.8 billion cash deal to acquire Atai Beckley, aiming to push a DMT-like therapy for tr...
A trio of midstream dividend ETFs yielding more than 5% are delivering market-beating performance, offering both inco...
MercadoLibre fell in February amid margin concerns and tougher competition in LATAM. This article breaks down the for...
Investors are watching intuitive machines (lunr) earnings to gauge how a private space era company translates NASA co...
A watershed moment hit crypto markets as bitcoin etfs shed $630m in one day. This article breaks down what drove the ...
A notable fund just built a fresh position in a cloud security leader. Discover the numbers behind winmill loads qual...
Two distinct paths define today’s energy investing: steady income from traditional infrastructure or high-octane grow...
In 2026, investors face a choice between a specialized look at nuclear power and the broader oil and gas market. This...
Arm Holdings faces a cooling pullback after a strong rally, offering a potential entry point for long-term investors....
Even as alkami stock down 50% frames a challenging chapter, a new large stake in Alkami Technology points to a differ...
A new AI risk assessment shows programmers face high displacement risk, upending traditional SaaS models and pressuri...
SCHB and VTV offer low-cost ways to invest in U.S. stocks, but they serve different purposes. One captures the broad ...